Researchers have discovered that plant-derived phytochemicals and their gut microbiome metabolites control the effectiveness ...

Explore how cutting-edge agents like alpelisib, capivasertib, MEK and ERK inhibitors, and JAK inhibitors are reshaping the ...

Kazia Therapeutics Limited (NASDAQ: KZIA) ("Kazia" or the "Company"), an oncology-focused biotechnology company developing ...

Kazia Therapeutics ( ($KZIA) ) just unveiled an update. On June 5, 2025, Kazia Therapeutics announced the dosing of the first patient in a Phase ...

A new triple-drug treatment for aggressive advanced breast cancer can cut deaths by a third, a major trial has found.

The ItovebiTM (inavolisib)-based regimen reduced the risk of death by more than 30% in people with PIK3CA-mutated HR-positive ...

Transwell assay showing increased invasion in SNB19 and U251 glioma cells transfected with FAM111B-overexpressing lentivirus, compared to controls. Magnification ×20 Study shows FAM111B overexpression ...

Roche’s blockbuster vision for phosphoinositide 3-kinase (PI3K inhibitor) Itovebi (inavolisib) has been dealt a boost after the drug demonstrated further positive overall survival (OS) data in a ...

A “breakthrough” new three-drug combination offers hope for women battling an aggressive form of breast cancer, potentially ...